Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Peer Review reports

Original Submission
3 Mar 2023	Submitted	Original manuscript
27 Mar 2023	Reviewed	Reviewer Report
12 Apr 2023	Reviewed	Reviewer Report - Hiba El Masri
2 May 2023	Author responded	Author comments - Pattara Leelahavarong
Resubmission - Version 2
2 May 2023	Submitted	Manuscript version 2
20 May 2023	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
23 May 2023	Editorially accepted
31 May 2023	Article published	10.1186/s12913-023-09595-1

Back to article page